Johanna Mercier
Known title: Chief Comm & Corp Aff OfficerCIK: 0001782135
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
Transaction History
| GILD | ▼ Sell | Open Market | 1,600 | $230K | 9/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 800 | $116K | 9/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 600 | $87K | 9/15/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,797 | — | 9/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,347 | $195K | 9/10/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 1,890 | $137K | 8/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 16,530 | $2.3M | 8/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 11,470 | $1.6M | 8/17/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 23,110 | $1.5M | 8/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $390K | 7/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 1,480 | $183K | 6/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 1,070 | $133K | 6/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 450 | $56K | 6/15/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,796 | — | 6/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,341 | $163K | 6/10/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,318 | $0 | 5/21/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 8,374 | $1.1M | 5/15/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 25,000 | $1.7M | 5/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 7,749 | $1.0M | 5/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 11,177 | $1.5M | 5/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 700 | $93K | 5/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $423K | 4/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $433K | 3/16/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 6,617 | — | 3/10/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 3,216 | $478K | 3/10/2026 | View on chart |
| GILD | ▲ Buy | Grant | 11,090 | $0 | 2/27/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 25,000 | $1.7M | 2/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 18,405 | $2.8M | 2/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 9,395 | $1.5M | 2/17/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 200 | $31K | 2/17/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 24,800 | $3.6M | 2/3/2026 | View on chart |
| GILD | ▲ Buy | Grant | 44,867 | $0 | 2/3/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $373K | 1/15/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $366K | 12/15/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,842 | — | 12/10/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,814 | $220K | 12/10/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 25,524 | $3.2M | 11/17/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 2,476 | $313K | 11/17/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 25,000 | $1.7M | 11/17/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $354K | 10/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $341K | 9/15/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,819 | $210K | 9/10/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,844 | — | 9/10/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 2,800 | $332K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 11,800 | $1.4M | 8/15/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 700 | $47K | 8/15/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 11,800 | $786K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 11,800 | $1.4M | 8/15/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 700 | $47K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 700 | $83K | 8/15/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 11,800 | $786K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 200 | $24K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 700 | $83K | 8/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $333K | 7/15/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $331K | 6/16/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,843 | — | 6/10/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,827 | $201K | 6/10/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 12,500 | $833K | 5/22/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 12,500 | $1.3M | 5/22/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 12,500 | $833K | 5/22/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 12,500 | $1.3M | 5/22/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 3,000 | $323K | 5/22/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,435 | $0 | 5/22/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 8,080 | — | 3/10/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 3,907 | $458K | 3/10/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 45,666 | $4.5M | 2/4/2025 | View on chart |
| GILD | ▲ Buy | Grant | 19,793 | $0 | 2/4/2025 | View on chart |
| GILD | ▲ Buy | Grant | 70,712 | $0 | 2/4/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,752 | — | 12/10/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,739 | $161K | 12/10/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 5,000 | $456K | 11/6/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 15,925 | $1.3M | 9/12/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 13,432 | $1.1M | 9/12/2024 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,752 | — | 9/10/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,734 | $141K | 9/10/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 9,513 | $742K | 8/28/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 5,490 | $406K | 8/13/2024 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,751 | — | 6/10/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,714 | $112K | 6/10/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,100 | $0 | 5/17/2024 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,025 | — | 3/10/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 4,559 | $342K | 3/10/2024 | View on chart |
| GILD | ▲ Buy | Option Exercise | 6,819 | — | 3/10/2024 | View on chart |
| GILD | ▲ Buy | Grant | 53,969 | $0 | 1/31/2024 | View on chart |
| GILD | ▲ Buy | Grant | 20,086 | $0 | 1/31/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 22,509 | $1.8M | 1/31/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 8,242 | $702K | 1/9/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,247 | $99K | 12/10/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,730 | — | 12/10/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,730 | — | 9/10/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,256 | $95K | 9/10/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 7,505 | — | 7/24/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 3,174 | $246K | 7/24/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,730 | — | 6/10/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 1,272 | $99K | 6/10/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 5,116 | $407K | 3/10/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,025 | — | 3/10/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 7,951 | — | 3/10/2023 | View on chart |
| GILD | ▲ Buy | Grant | 38,270 | $0 | 1/24/2023 | View on chart |
| GILD | ▲ Buy | Grant | 29,124 | $0 | 1/24/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 15,325 | $1.3M | 1/24/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 990 | — | 12/10/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 463 | $41K | 12/10/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 458 | $30K | 9/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 990 | — | 9/10/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 3,206 | $195K | 7/24/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 7,505 | — | 7/24/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 462 | $28K | 6/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 990 | — | 6/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,962 | $0 | 3/10/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 3,221 | $187K | 3/10/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 3,025 | $0 | 3/10/2022 | View on chart |
| GILD | ▲ Buy | Grant | 18,630 | $0 | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.